Innovative Oral Delivery Intract Pharma specializes in transforming injectable biologics into oral pills, providing a significant market opportunity in the development of patient-friendly treatments for chronic immune-mediated diseases.

Strategic Partnerships The company's recent collaborations with industry leaders like Tharimmune, Bio-Thera Solutions, and Celltrion highlight its strong position to expand licensing and co-development deals, opening avenues for joint commercialization.

Targeted Disease Focus Intract’s focus on gastrointestinal and systemic inflammatory diseases offers sales potential within highly active pharmaceutical markets for biologic treatments addressing conditions like Crohn’s disease and rheumatoid arthritis.

Technology Leadership With proprietary platforms such as Phloral™ and Soteria™, Intract Pharma can offer advanced drug delivery solutions that appeal to biopharma firms seeking innovative oral biologic formulations.

Funding and Development Potential Ongoing projects including scalable manufacturing processes and recent UK government funding position Intract as a promising partner for pharmaceutical companies looking to accelerate oral biologic development and commercialization.